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Abstract 
Background: Combination therapy with canagliflozin and insulin was investigated in a prescribed substudy of 
the canagliflozin Cardiovascular Assessment Study (CANVAS); however, it was not evaluated in Japanese patients 
with type 2 diabetes mellitus (T2DM). Since the usage profile of insulin therapy and pathologic features of Japanese 
patients differ from those of Caucasian patients, we determined the clinical benefit of such a combination therapy in 
Japanese patients.
Methods: Patients who had inadequate glycemic control despite insulin, diet and exercise therapies were rand‑
omized into placebo (n = 70) and canagliflozin 100 mg (n = 76) groups that were administered once daily in addition 
to their prior insulin therapy in this double‑blind, placebo‑controlled study. The primary endpoint was the change in 
glycated hemoglobin (HbA1c) levels from the baseline to week 16.
Results: There was a statistically significant decrease in HbA1c levels from the baseline in the canagliflozin group 
(−0.97 ± 0.08 %) compared with the placebo group (0.13 ± 0.08 %) at week 16 [last observation carried forward 
(LOCF)]. The decrease in HbA1c levels in the canagliflozin group was independent of the insulin regimen (premixed, 
long‑acting and long‑acting plus rapid‑ or short‑acting). Compared with the placebo group, canagliflozin signifi‑
cantly decreased fasting plasma glucose levels (−34.1 ± 4.8 vs −1.4 ± 5.0 mg/dL) and body weights (−2.13 ± 0.25 
vs 0.24 ± 0.26 %), and significantly increased HDL cholesterol (3.3 ± 1.0 vs −0.5 ± 1.0 mg/dL) and HOMA2‑ %B 
(10.15 ± 1.37 vs 0.88 ± 1.42 %). The overall incidence of adverse events was similar between the two groups. The inci‑
dence and incidence per subject‑year exposure of hypoglycemia (hypoglycemic symptoms and/or decreased blood 
glucose) were slightly higher in the canagliflozin group (40.0 % and 7.97) than in the placebo group (29.6 % and 4.51). 
However, hypoglycemic events in both groups were mild in severity and dose‑reduction of insulin by <10 % from 
the baseline following hypoglycemic events decreased the incidence per subject‑year exposure in the canagliflozin 
group. The incidence of hypoglycemia between the groups did not differ according to the insulin regimen.
Conclusion: Canagliflozin in combination with insulin was effective in improving glycemic control and reducing 
body weight and well tolerated by Japanese patients with T2DM.
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Background
Type 2 diabetes mellitus (T2DM) is a worldwide problem 
that is growing in prevalence. The International Diabetes 
Federation estimates that 382 million people had diabetes 
globally in 2013 and predicts that 592 million people will 
suffer from the disease in 2035 [1]. Chronic hyperglyce-
mia caused by diabetes is associated with microvascular 
and macrovascular complications, which deteriorate the 
quality of life and increase cardiovascular events. There-
fore, glycemic control is important to prevent diabetic 
complications and to maintain quality of life [2].
T2DM is conventionally treated with insulin secreta-
gogues, insulin sensitizers, glucose absorption inhibitors, 
insulin, and glucagon-like peptide-1 receptor agonists 
[2, 3]. Intensive glycemic control with insulin therapy 
prevents diabetic complications [4–6]. However, insulin 
therapy is associated with the risk of hypoglycemia and 
weight gain [7–9]. Moreover, weight gain may exacerbate 
insulin resistance, resulting in the need for an increased 
dose of insulin, which may cause further weight gain. In 
addition, the effect of blood glucose, rate of hypoglyce-
mia, and weight gain differ among insulin regimens [10]. 
Therefore, it is important to determine the insulin regi-
men according to the patient’s background [3].
Inhibitors of the sodium glucose co-transporter 2 
(SGLT2) suppress glucose reabsorption in renal tubules 
and exert insulin-independent antihyperglycemic effects. 
In addition, this class of drugs decreases body weight 
[11, 12]. The SGLT2 inhibitor canagliflozin has been 
approved for the treatment of T2DM by the regulatory 
authorities of numerous countries across North Amer-
ica, Europe, Latin America, and Asia–Pacific [13]. The 
efficacy and safety of canagliflozin monotherapy and in 
combination with other oral antihyperglycemic agents 
were demonstrated by studies conducted in Japan [14, 
15]. Combination therapy with canagliflozin and insulin 
was investigated in a prescribed sub study of the cana-
gliflozin Cardiovascular Assessment Study (CANVAS) 
[16]. However, the effects of a combination of canagli-
flozin and insulin in Japanese patients with T2DM have 
not been investigated. The usage profile of insulin ther-
apy and pathologic features of Japanese patients differ 
from those of Caucasian patients [17–19]. Therefore, 
it is important to determine the clinical benefit of such 
a combination therapy in Japanese patients. In the pre-
sent study, we evaluated the efficacy and safety of cana-
gliflozin in combination with insulin in Japanese patients 
with T2DM who had inadequate glycemic control despite 
insulin, diet, and exercise therapies. We further assessed 




We conducted a randomized, parallel-group, double-
blind study to evaluate the efficacy and safety of cana-
gliflozin in Japanese patients with T2DM who had 
inadequate glycemic control despite insulin, diet and 
exercise therapies (Fig.  1). After a 4-week single-blind 
run-in period, eligible patients were randomized and 
administered placebo or 100  mg of canagliflozin once 
daily before breakfast for 16 weeks. Randomization was 
performed using a block allocation method (1:1, block 
sizes of 4 and 87 blocks).
The patients received one of the insulin regimens as 
follows: premixed, intermediate-acting, long-acting, pre-
mixed plus rapid- or short-acting, intermediate-acting 
plus rapid- or short-acting, long-acting plus rapid- or 
short-acting. The daily dose of insulin ranged from 8 to 
60  units. In principle, the insulin dose was fixed dur-
ing the study period; however, the change within ±10 % 
of the total daily dose of insulin from the baseline was 
allowed in order to avoid or treat hypoglycemia or other 
concomitant illnesses.
Compliance with the declaration of Helsinki and informed 
consent
This study was conducted in the spirit of the ethical prin-
ciples grounded in the declaration of Helsinki and in 
compliance with Japanese laws related to ensuring drug/
medical device quality, efficacy, and safety and Japanese 
ministerial orders and related regulations on good post-
marketing surveillance practice and good clinical prac-
tice. The study was approved by the ethics committee/
instructional review boards at all of the participating 
institutions (see List of participating investigators under 
"Acknowledgements" section). All patients provided writ-
ten informed consent.
Inclusion and exclusion criteria
Criteria for including patients were as follows: fixed diet 
and exercise therapy, receiving a stable dose and regimen 
of insulin over the 12 weeks before the start of treatment 
(week 0), glycated hemoglobin (HbA1c) levels of ≥7.5 
to <10.5 %, and not taking prohibited antidiabetic drugs 
during the 12 weeks before week 0. Criteria for excluding 
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patients were as follows: type 1 DM (T1DM), DM caused 
by a pancreatic disorder, or secondary DM (e.g. Cush-
ing’s syndrome and acromegaly); severe diabetic com-
plications (proliferative diabetic retinopathy, stage 4 
nephropathy, or serious diabetic neuropathy); hereditary 
glucose–galactose malabsorption or primary renal glyco-
suria; systolic blood pressure of ≥160 mmHg or diastolic 
blood pressure of ≥100 mmHg; serious renal or hepatic 
disease; estimated glomerular filtration rate of  <45  mL/
min/1.73  m2; alcoholics; pregnant or possibly pregnant; 
breastfeeding a child; and refusal to use contraception.
Outcome measures
The primary endpoint was the change in HbA1c lev-
els from the baseline to week 16 [last observation car-
ried forward (LOCF)]. The secondary endpoints were the 
changes from the baseline in HbA1c levels at each evalu-
ation point, fasting plasma glucose (FPG), body weight, 
systolic and diastolic blood pressure, lipids [fasting triglyc-
erides, high-density lipoprotein (HDL) cholesterol], fasting 
proinsulin/C-peptide ratio, and homeostasis model assess-
ment 2 steady-state beta-cell function (HOMA2-  %B). 
HOMA2-  %B was calculated using FPG and fasting 
C-peptide values. An Excel version of the HOMA calcula-
tor of the Diabetes Trial Unit at the University of Oxford 
was used to calculate HOMA2- %B values.
Safety was assessed based on adverse events, hypogly-
cemic events, and laboratory test values. AEs were judged 
by the physicians, and the numbers of affected patients 
and incidence are listed using MedDRA (Ver. 18.0) 
system organ class and preferred term. Further, study 
patients performed self-monitoring of fasting blood glu-
cose at least 3  days each week and when experiencing 
hypoglycemic symptoms. Low blood glucose without 
symptoms (≤70 mg/dL) was classified as decreased blood 
glucose. Hypoglycemic episodes with a typical hypogly-
cemic symptom were classified as hypoglycemia, regard-
less of the blood glucose level.
Statistical analysis
For the primary and secondary endpoints, point esti-
mates of intergroup difference (canagliflozin group − pla-
cebo group) in least squares (LS) means were calculated 
along with the corresponding standard error (SE), 95  % 
confidence interval, and p value. Analysis of covariance 
(ANCOVA) was performed to determine absolute or 
percentage changes from the baseline to each evaluation 
point, with the baseline value as a covariate. Changes in 
HbA1c levels from the first day of treatment to each eval-
uation point were analyzed using mixed-model repeated-
measures (MMRM) with restricted maximum likelihood. 
All statistical analyses were conducted using SAS 9.4 
(SAS Institute Inc., Cary, NC, USA)
Results
Patient disposition and demographic characteristics
Of the 201 patients who consented to participate, 186 
entered in the run-in period, and 146 patients were ran-
domized for treatment with placebo (n = 70) or canagli-
flozin (n  =  76). One patient in the canagliflozin group 
Insulin (fixed dose for ≥8 weeks before the run-in period)*







Run-in period Treatment period
(4 weeks) (16 weeks)
Follow-up period
(2 weeks)
−12W − 4W 16W0W 18W
Randomizaon
Wash out of an-diabec drugs 
except insulin
Fig. 1 Study design. Asterisk accepted when the difference between daily doses of each insulin product and total insulin products were ±10 % of 
those on the first day of treatment
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was mistakenly administered placebo. This patient was 
included in the canagliflozin group in the full analysis set 
and in the placebo group in the safety analysis set (Addi-
tional file 1: Figure S1).
Table  1 shows patient characteristics of the full analy-
sis set. In the placebo and canagliflozin groups, mean 
ages were 56.1 and 59.7  years, body weights were 69.68 
and 69.95  kg, and durations of T2DM were 12.34 and 
15.18 years, respectively. The mean HbA1c levels were 8.85 
and 8.89 %, and FPG levels were 169.1 and 169.9 mg/dL in 
the placebo and canagliflozin groups, respectively (Table 1).
The mean daily dose of insulin was 28.1 units in the 
placebo group and 31.1 units in the canagliflozin group, 
and was not remarkably different between the regimens 
of the placebo and canagliflozin groups: premixed insu-
lin, 29.0 and 33.1 units; long-acting insulin, 20.9 and 20.5 
units; and long-acting and rapid- or short-acting insu-
lin, 36.7 and 39.5 units, respectively. No patient used an 
intermediate-acting insulin product (Table 1).
Efficacy
The changes in HbA1c levels from the baseline at week 
16 (LOCF, LS mean  ±  SE) were 0.13  ±  0.08  % in the 
placebo group and −0.97  ±  0.08  % in the canagliflozin 
group, corresponding to the placebo-adjusted changes of 
−1.10 % (95 % CI, −1.33 to −0.87; p < 0.001), which were 
statistically significant. The MMRM were also statistically 
significant between the groups (p < 0.001), indicating the 
robustness of the results (Table 2). The statistically signif-
icant decrease in HbA1c levels in the canagliflozin group 
compared with the placebo group were apparent at week 
4 and reached a plateau at week 12, which were main-
tained until week 16 (all; p < 0.001) (Fig. 2). The decrease 
in HbA1c levels in the canagliflozin group was observed 
independent of the type of insulin regimen (Table 2).







 Male 49 (70.0) 44 (57.9)
 Female 21 (30.0) 32 (42.1)
Age (years)
 Mean ± SD 56.1 ± 10.9 59.7 ± 9.4
Duration of diabetes (years)
 Mean ± SD 12.34 ± 8.21 15.18 ± 8.61
Body weight (kg)
 Mean ± SD 69.68 ± 13.13 69.95 ± 13.93
BMI (kg/m2)
 Mean ± SD 25.99 ± 4.40 26.88 ± 4.82
Waist circumference (cm)
 Mean ± SD 90.80 ± 10.97 92.93 ± 11.87
Diabetic complications, N (%)
 All 48 (68.6) 50 (65.8)
 Retinopathy 26 (37.1) 35 (46.1)
 Neuropathy 13 (18.6) 14 (18.4)
 Nephropathy 28 (40.0) 31 (40.8)
Nondiabetic complications, N (%)
 Hypertension 40 (57.1) 48 (63.2)
 Dyslipidemia 49 (70.0) 63 (82.9)
HbA1c (%)
 Mean ± SD 8.85 ± 0.84 8.89 ± 0.81
Fasting plasma glucose (mg/dL)
 Mean ± SD 169.1 ± 52.6 169.9 ± 44.4
Fasting C‑peptide (ng/mL)
 Mean ± SD 1.018 ± 0.776 0.959 ± 0.703
HOMA2‑ %B (%)
 Mean ± SD 24.18 ± 13.84 22.62 ± 11.24
eGFR (mL/min/1.73 m2)
 Mean ± SD 86.1 ± 21.7 83.8 ± 18.4
Daily dose of insulin (unit)
 Mean ± SD 28.1 ± 14.0 31.1 ± 15.1
Daily dose of insulin by insulin regimen (unit)
 Premixed
  N 26 28
  Mean ± SD 29.0 ± 11.6 33.1 ± 14.7
 Intermediate‑acting
  N 0 0
  Mean ± SD – –
 Long‑acting
  N 24 24
  Mean ± SD 20.9 ± 12.2 20.5 ± 12.3
 Premixed + rapid‑or short‑acting






  Mean ± SD 16.0 –
Intermediate + rapid‑or short‑acting
  N 0 0
  Mean ± SD – –
 Long‑acting + rapid‑or short‑acting
  N 19 24
  Mean ± SD 36.7 ± 14.9 39.5 ± 12.1
N number of patients, BMI body mass index, HOMA2- %B homeostasis model 
assessment 2 steady state beta cell function, eGFR, estimated glomerular 
filtration rate
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A significant decrease in FPG in the canagliflozin group 
compared with the placebo group was detected by week 4 
and was maintained until week 16 (all; p < 0.001) (Fig. 3a). 
The difference between the canagliflozin and placebo 
groups regarding the change in FPG (LOCF,LS mean) was 
−32.6 mg/dL (95 % CI, −46.3 to −18.9; p < 0.001) (Table 3).
The mean body weight of the canagliflozin group signif-
icantly decreased from weeks 4 to 12 and was maintained 
through week 16 (all; p < 0.001) (Fig. 3b). The difference 
between the canagliflozin and the placebo groups regard-
ing the percentage change in body weight from the base-
line to week 16 (LOCF, LS mean) was −2.37 % (95 % CI, 
−3.09 to −1.65; p < 0.001) (Table 3).
Other secondary endpoints, including the changes from 
the baseline to week 16 of systolic and diastolic blood 
pressures, triglycerides, HDL cholesterol, proinsulin/C-
peptide ratio, and HOMA2-  %B are summarized in 
Table  3. The systolic and diastolic blood pressure and 
triglycerides were decreased from baseline at week 16 
in the canagliflozin group; however, there was no sig-
nificant difference between the canagliflozin and placebo 
groups. HDL cholesterol was significantly increased in 
the canagliflozin group compared to the placebo group 
after 12  weeks of treatment, and the difference between 
two groups (LOCF, LS mean) was 3.7  mg/dL (95  % CI, 
1.0–6.5; p = 0.007). The difference between the canagliflo-
zin and placebo groups regarding the change in the fast-
ing proinsulin/C-peptide ratio and HOMA2- %B (LOCF, 
LS mean), as markers of beta cell function, was −0.0026 
(95 % CI, −0.0070 to 0.0017; p = 0.235) and 9.27 % (95 % 
CI, 5.35–13.19; p < 0.001), respectively (Table 3).
The insulin doses were increased in 10 patients (14.3 %) 
and three patients (3.9  %); increased and decreased in 
one patient (1.4 %) and one patient (1.3 %); and decreased 
in two patients (2.9 %) and 13 patients (17.1 %) in the pla-
cebo and canagliflozin groups, respectively.
Safety
The overall incidence of adverse events was simi-
lar between the two groups (64.8  %, placebo group; 
Table 2 Effect of canagliflozin on HbA1c levels
N number of patients, LS mean least squares mean, 95 % CI 95 % confidence 
interval
a LS mean for change from the baseline to week 16, ANCOVA (Factor treatment, 
covariate HbA1C levels at baseline)




 N 70 76
 Mean (SD) baseline (%) 8.85 (0.84) 8.89 (0.81)
 LS mean (SE) change (%)a 0.13 (0.08) −0.97 (0.08)
 Difference (95 % CI) vs placebo (%) – −1.10 (−1.33, −0.87)
 p value <0.001
 N 66 73
 LS mean (SE) change (%)b 0.15 (0.08) −0.98 (0.08)
 Difference (95 % CI) vs placebo (%) – −1.13 (−1.36, −0.89)
 p value – <0.001
Each insulin regimen
 Premixed
  N 26 28
  Mean (SD) baseline (%) 8.70 (0.82) 8.73 (0.73)
  LS mean (SE) change (%)a −0.01 (0.13) −0.89 (0.12)
  Difference (95 % CI) vs placebo 
(%)
– −0.88 (−1.24, −0.52)
  p value – <0.001
 Long‑acting
  N 24 24
  Mean (SD) baseline (%) 8.89 (0.85) 9.02 (0.87)
  LS mean (SE) change (%)a 0.26 (0.12) −1.18 (0.12)
  Difference (95 % CI) vs placebo 
(%)
– −1.44 (−1.79, −1.09)
  p value – <0.001
 Premixed + rapid‑ or short‑acting
  N 1 0
  Mean (SD) baseline (%) 7.50 (−) –
  LS mean (SE) change (%)a 0.10 (0.00) –
 Long‑acting + rapid‑ or short‑acting
  N 19 24
  Mean (SD) baseline (%) 9.09 (0.80) 8.96 (0.83)
  LS mean (SE) change (%)a 0.17 (0.19) −0.83 (0.17)
  Difference (95 % CI) vs placebo 
(%)
– −1.00 (−1.51, −0.49)
























0 4 8 12 16
Placebo
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Fig. 2 Time course of the change in HbA1c levels from the baseline. 
Each point and bar represents LS mean ± SE. *p < 0.001 vs placebo 
by ANCOVA. The number of patients at each point is shown in the 
lower table. N number of patients at each point, 16 (LOCF) last obser‑
vation carried forward to week 16
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68.0  %, canagliflozin group). The adverse events that 
occurred more frequently in the canagliflozin group were 
decreased blood glucose, hypoglycemia, pollakiuria, and 
polyuria (Table  4). The incidence of hypoglycemia was 
slightly higher in the canagliflozin group (40.0  %) than 
in the placebo group (29.6 %). The difference in the inci-
dence ratio between the placebo and canagliflozin groups 
was 10.4 %, which was not statistically significant (95 % 
CI, −6.0 to 26.3; p = 0.225), and all hypoglycemic events 
were mild in severity.
The mean daily insulin dose during treatment was 29.7 
units. Hypoglycemic events occurred similarly in patients 
receiving lower (<29.7 units), equal, or higher than (≥29.7 
units) the average insulin dose. The incidence of hypogly-
cemia in patients receiving an insulin dose of <29.7 units 
or ≥29.7 units was 27.5 % (n = 11) or 32.3 % (n = 10), 
respectively, in the placebo group and 39.5 % (n = 15) or 
40.5 % (n = 15), respectively, in the canagliflozin group.
The incidence of hypoglycemia and incidence per sub-
ject-year exposure did not differ substantially accord-
ing to the type of insulin regimen received by either 
the placebo group or the canagliflozin group (Table  5). 
Additional file  2: Table S1 summarizes the incidence of 
hypoglycemia at 0:00–5:59, 6:00–11:59, 12:00–17:59, 
and 18:00–23:59  h. The hypoglycemic events occurred 
most frequently between 6:00 and 11:59 h. Furthermore, 
the incidence of hypoglycemia of both groups was not 
associated with exposure period (data not shown). The 
incidence of hypoglycemia per subject-year exposure 
was higher in the canagliflozin group (7.97) than in the 
placebo group (4.51) (Table 5). For patients whose insu-
lin dose was decreased by the investigator because of a 
hypoglycemic event, the incidence rate of hypoglycemia 
per subject-year exposure decreased with dose reduction 
in the canagliflozin group, regardless of the type of insu-
lin regimen (Table 6).
Adverse events related to osmotic diuresis occurred 
slightly more frequently in the canagliflozin group 
than in the placebo group, but adverse events related 
to volume depletion, which could occur secondarily 
to osmotic diuresis, were not observed in either group 
(Table 4).
Serious adverse events were as follows: cataracts (one 
patient on placebo and one patient on canagliflozin), reti-
nal detachment (one patient on canagliflozin), vitreous 
hemorrhage (one patient on canagliflozin), and alcoholic 
liver disease (one patient on canagliflozin). However, a 
causality assessment of “not related” was assigned to each 
event. Alcoholic liver disease (in one patient on canagli-
flozin) resulted in withdrawal from the study.
Small increases in hemoglobin, hematocrit, and blood 
urea nitrogen levels were detected in the canagliflozin 
group. AST, ALT and γ-GTP levels were decreased from 
baseline in the canagliflozin group. The change of LDL-C 
was not different between placebo and canagliflozin 
groups. The mean value of the ketone bodies at baseline 
of both groups was higher than normal range, which was 
defined as 26.0–122 μmol/L in this study, and the slight 
increase of the ketone bodies was observed at 16 weeks 
in canagliflozin group (Additional file 3: Table S2).
Evaluaon Point  
(week)
4 8 12 16 16
(LOCF)
Placebo N 70 67 68 66 70
Canagliflozin 100 mg N 75 74 74 73 75
Evaluaon Point  
(week)
4 8 12 16 16
(LOCF)
Placebo N 70 68 69 66 70
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Fig. 3 Time courses of the change in (a) fasting plasma glucose (FPG) and (b) body weight from the baseline. Each point and bar represents the 
LS mean ± SE. *p < 0.001 vs placebo by ANCOVA. The number of patients at each point is shown in the lower table. N number of patients at each 
point, 16 (LOCF) last observation carried forward to week 16
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Discussion
Current findings and implications: efficacy
In the present study, treatment with canagliflozin for 
16 weeks improved glycemic control and other metabolic 
parameters, such as body weight and HDL cholesterol, 
in Japanese patients with T2DM who received insulin 
therapy. The decrease in HbA1c levels here was slightly 
greater than that observed in a previous study in non-Jap-
anese patients, including Caucasians [difference between 
placebo and canagliflozin (100  mg each) at 18  weeks, 
−0.62 %] [16], suggesting that the effects of canagliflozin 
are independent of the pathologic features among races 
[20]. A significant decrease in HbA1c levels was observed 
regardless of the type of the insulin regimen.
Administration of insulin to patients with T2DM is 
often associated with weight gain, but the patients stud-
ied here experienced weight loss following combination 
therapy with canagliflozin and insulin. Similar results 
were reported by studies on the SGLT2 inhibitors dapa-
gliflozin and empagliflozin used in combination with 
insulin, which were conducted outside Japan [21–24].
A study on a Japanese population administered a com-
bination therapy of dapagliflozin and insulin demon-
strated the improving glycemic control and reducing body 
weight. However, there are some differences in the present 
study: about 45  % of the participants were also treated 
with a dipeptidyl peptidase-4 inhibitor, and the data were 
not evaluated according to the type of insulin regimen 
[25]. The results of the present study demonstrated that 
the combination of canagliflozin and insulin, regardless 
of the insulin regimen, controlled plasma glucose levels 
without causing weight gain in Japanese patients with 
T2DM who were inadequately controled by insulin.
Japanese patients with T2DM tend to have a long 
duration of disease and have high levels of HbA1c 
Table 3 Effect of canagliflozin on secondary endpoints
Parameters Placebo Canagliflozin 100 mg
FPG (mg/dL)
 N 70 75
 Mean (SD) baseline 169.1 (52.6) 170.6 (44.4)
 LS mean (SE) changea −1.4 (5.0) −34.1 (4.8)
 Difference (95 % CI) vs 
placebo
– −32.6 (−46.3, −18.9)
 p value – <0.001
Body weight (kg)
 N 70 75
 Mean (SD) baseline 69.68 (13.13) 70.19 (13.86)
 LS mean (SE) changea 0.15 (0.18) −1.49 (0.18)
(%)
 LS mean (SE) percent 
changea
0.24 (0.26) −2.13 (0.25)
 Difference (95 % CI) vs 
placebo
– −2.37 (−3.09, −1.65)
 p value – <0.001
SBP (mmHg)
 N 70 76
 Mean (SD) baseline 129.95 (16.32) 136.85 (12.01)
 LS mean (SE) changea −0.40 (1.19) −3.58 (1.14)
 Difference (95 % CI) vs 
placebo
– −3.19 (−6.49, 0.11)
 p value – 0.058
DBP (mmHg)
 N 70 76
 Mean (SD) baseline 77.23 (10.87) 78.34 (10.18)
 LS mean (SE) changea −0.31 (0.74) −1.55 (0.71)
 Difference (95 % CI) vs 
placebo
– −1.24 (−3.27, 0.80)
 p value – 0.232
Triglyceride (mg/dL)
 N 70 75
 Mean (SD) baseline 144.0 (114.0) 124.5 (112.3)
 LS mean (SE) changea −4.0 (7.7) −7.8 (7.4)
 Difference (95 % CI) vs 
placebo
– −3.8 (−25.0, 17.3)
 p value – 0.721
HDL‑cholesterol (mg/dL)
 N 70 75
 Mean (SD) baseline 57.6 (16.9) 61.9 (16.1)
 LS mean (SE) changea −0.5 (1.0) 3.3 (1.0)
 Difference (95 % CI) vs 
placebo
– 3.7 (1.0, 6.5)
 p value – 0.007
Proinsulin/C‑peptide
 N 69 74
 Mean (SD) baseline 0.0267 (0.0323) 0.0235 (0.0380)
 LS mean (SE) changea 0.0003 (0.0016) −0.0024 (0.0015)
 Difference (95 % CI) vs 
placebo
– −0.0026 (−0.0070, 0.0017)
N number of patients, FPG fasting plasma glucose, SBP systolic blood pressure, 
DBP diastolic blood pressure, HDL-cholesterol high-density lipoprotein 
cholesterol, HOMA2- %B homeostasis model assessment 2 steady state beta cell 
function, LS mean least squares mean, 95 % CI, 95 % confidence interval
a LS mean for change from the baseline to week 16, (factor treatment, covariate 
each parameter at baseline)
Table 3 continued
Parameters Placebo Canagliflozin 100 mg
 p value – 0.235
HOMA2‑ %B (%)
 N 69 74
 Mean (SD) baseline 24.26 (13.92) 22.23 (11.12)
 LS mean (SE) changea 0.88 (1.42) 10.15 (1.37)
 Difference (95 % CI) vs 
placebo
– 9.27 (5.35, 13.19)
 p value – <0.001
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when insulin is initiated [17, 18]. Patients in the pre-
sent study had a longer duration of DM (approximately 
12–15  years) than that of previous studies (approxi-
mately 5–8  years in the Japanese phase 3 study) and a 
higher baseline level of HbA1c [14, 15]. Baseline values 
of HOMA2- %B and C-peptide were lower in the present 
study than in those previously reported, which suggests 
that the patients had a decreased capacity to secrete insu-
lin. Nevertheless, canagliflozin treatment improved gly-
cemic control. These findings are consistent with those 
of previous studies showing that canagliflozin decreases 
plasma glucose, regardless of insulin secretory capacity 
and duration of diabetes mellitus [26, 27]. Interestingly, 
canagliflozin combination with insulin slightly increased 
HOMA2-  %B, suggesting improved beta-cell function. 
This is possibly resulting from a reduction of glucotoxic-
ity [12, 28].
Current findings and implications: Safety
Here the overall incidence of adverse events was similar 
between the placebo and canagliflozin groups. The inci-
dence of hypoglycemia was slightly higher in the canagli-
flozin group than in the placebo group. All events were 
mild in severity, and severe hypoglycemia (i.e., requir-
ing the assistance of another person) was not reported. 
Hypoglycemic events (hypoglycemic symptoms and/or 
decreased blood glucose) occurred most frequently at 
6:00–11:59 h; therefore, caution may be exercised in the 
morning for patients who receive the combination of an 
SGLT2 inhibitor and insulin.
The incidence of hypoglycemia was not markedly dif-
ferent among the types of insulin regimens. In a study 
on empagliflozin added on to basal insulin, during the 
first 18  weeks of administration of a fixed insulin dose, 
the incidence of hypoglycemic events was slightly higher 
Table 4 Summary of safety data (safety analysis set)
MedDRA Ver.18.0 N number of patients, n number of patients with adverse event,  % = n/N × 100
a Hypoglycemia in the follow-up period was excluded
Placebo Canagliflozin 100 mg
(N = 71) (N = 75)
n (%) 95 % CI n (%) 95 % CI
Adverse events 46 (64.8) 52.5–75.8 51 (68.0) 56.2–78.3
Adverse drug reactions 16 (22.5) 13.5–34.0 30 (40.0) 28.9–52.0
Serious adverse events 1 (1.4) 0.0–7.6 3 (4.0) 0.8–11.2
Serious adverse drug reactions 0 (0.0) 0.0–5.1 0 (0.0) 0.0–4.8
Adverse events leading to discontinuation 0 (0.0) 0.0–5.1 1 (1.3) 0.0–7.2
Adverse drug reactions leading to discontinuation 0 (0.0) 0.0–5.1 0 (0.0) 0.0–4.8
Deaths 0 (0.0) 0.0–5.1 0 (0.0) 0.0–4.8
AEs of special interest
 Documented hypoglycemiaa 21 (29.6) 30 (40.0)
  Hypoglycemia 15 (21.1) 19 (25.3)
  Blood glucose decreased 11 (15.5) 20 (26.7)
Urinary tract infection 0 (0) 1 (1.3)
 Cystitis 0 (0) 1 (1.3)
Osmotic diuresis 2 (2.8) 4 (5.3)
 Pollakiuria 1 (1.4) 4 (5.3)
 Polyuria 0 (0) 3 (4.0)
 Thirst 1 (1.4) 1 (1.3)
Fracture 1 (1.4) 0 (0)
 Foot Fracture 1 (1.4) 0 (0)
Skin disorder 0 (0) 2 (2.7)
 Seborrheic dermatitis 0 (0) 1 (1.3)
 Urticaria 0 (0) 1 (1.3)
Ketone bodies 2 (2.8) 3 (4.0)
 Blood ketone bodies increased 2 (2.8) 3 (4.0)
(Number of female patients) (N = 22) (N = 31)
Vulvovaginitis 0 (0) 1 (3.2)
 Genital candidiasis 0 (0) 1 (3.2)
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in patients administered 25  mg of empagliflozin than 
in those administered placebo or 10  mg of empagliflo-
zin. However, after physicians were allowed to titrate 
the insulin dose, the incidence of hypoglycemia over 
the complete 78-week treatment was similar among the 
groups [24]. Similarly, in the present study, the incidence 
per subject-year exposure decreased in patients under-
going insulin dose reduction following a hypoglycemic 
event. These findings suggest that adjusting the insulin 
dose of the combined regimen prevents the occurrence 
of hypoglycemic events.
The slight increase of the ketone bodies (59.93 μmol/L) 
from baseline was observed at 16 weeks in canagliflozin 
group, although it was not notably higher than those 
reported by previous studies of canagliflozin [14, 15, 
29] or other SGLT2 inhibitor [30]. Malaise and similar 
symptoms that may accompany the marked elevation of 
ketone bodies were not reported, and no patient was dis-
missed because of increased blood ketone bodies in this 
study. The elevation of ketone bodies was not accompa-
nied by hyperglycemia and is therefore likely attribut-
able to a compensatory increase in fatty acid metabolism 
in response to loss of calories because of canagliflozin-
induced urinary glucose excretion.
Future perspectives
Several clinical studies have reported the safety and effi-
cacy of SGLT2 inhibitors in combination with insulin in 
patients with T1DM, however diabetic ketoacidosis has 
been reported in some studies [28, 31–34]. In addition, 
diabetic ketoacidosis has been reported in patients with 
T1DM who were treated off-label with an SGLT2 inhibi-
tor in daily clinical practice [35, 36].Therefore application 
of SGLT2 inhibitors for T1DM still remains to be 
addressed.
On the other hand, some cases of diabetic ketoacido-
sis have also been reported in patients with T2DM who 
were treated with an SGLT2 inhibitor. Lowering the 
dose of insulin may increase the production of ketone 
bodies because of insufficient suppression of lipoly-
sis and ketogenesis [35]. Therefore adjusting the insulin 
dose may be performed with care, particularly in T2DM 
patients with diminished capacity to secrete insulin.
There were no cardiovascular-related AEs both pla-
cebo and canagliflozin group in this study. Several 
studies of SGLT2 inhibitors for assessment of the car-
diovascular outcome are conducting [37], and it was 
recently reported that the SGLT2 inhibitor empagliflzoin 
reduces cardiovascular event in T2DM patient with high 
CVD risk, EMPA-REG OUTCOME trial, around 48  % 
of subjects were on insulin-combination therapy [38]. In 
the CANVAS trial, about half of the subjects were also 
treated with insulin [39]. These studies will provide the 
information on the effect of the combination of SGLT2 
inhibitor and insulin on cardiovascular outcome.
Limitations of the study
The limitation of this study is the short course of treat-
ment; hence, the present study has been extended for up 
to 52 weeks. In addition, patients who were treated with 
insulin in the form of an intermediate-acting or rapid-
acting product were not involved, and there were a small 
number of patients in each type of insulin subgroup. 
Therefore, we did not discuss which insulin regime fit 
better with canagliflozin.
Table 5 Incidence of hypoglycemia classified according to insulin regimen
Hypoglycemia in the follow-up period was excluded
N number of patients, n number of subjects with adverse event,  % = n/N × 100





 Number of patients N = 71 N = 26 N = 24 N = 1 N = 20
 Hypoglycemia n (%) 21 (29.6) 6 (23.1) 5 (20.8) 1 (100.0) 9 (45.0)
 Cumulative exposure (subject‑year) 21.3 7.87 7.25 0.31 5.88
 Number of events 96 33 29 3 31
 Incidence per subject‑year exposure 4.51 4.19 4.00 9.78 5.28
Canagliflozin 100 mg
 Number of patients N = 75 N = 28 N = 24 – N = 23
 Hypoglycemia n (%) 30 (40.0) 12 (42.9) 8 (33.3) – 10 (43.5)
 Cumulative exposure (subject‑year) 22.57 8.35 7.17 7.06
 Number of events 180 50 64 66
 Incidence per subject‑year exposure 7.97 5.99 8.93 9.35
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Conclusion
Canagliflozin added to insulin therapy was effective and 
well tolerated by Japanese patients with T2DM. This regi-
men provides a novel option in the treatment of patients 
with T2DM who require additional treatment.
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 Before first dose reduction
  Cumulative exposure  
(subject‑year)
0.72 0.23 0.26 0.23 –
  Number of events 16 14 0 2 –
  Incidence per subject‑year 
exposure
22.31 60.88 0 8.70 –
 After first dose reduction
  Cumulative exposure  
(subject‑year)
0.18 0.08 0.03 0.08 –
  Number of events 5 4 0 1 –
  Incidence per subject‑year 
exposure
27.26 52.18 0 13.04 –











 Before first dose reduction
  Cumulative exposure  
(subject‑year)
1.54 0.42 0.59 – 0.53
  Number of events 72 22 20 – 30
  Incidence per subject‑year 
exposure
46.88 52.87 33.98 – 56.48
 After first dose reduction
  Cumulative exposure  
(subject‑year)
2.55 0.64 0.93 – 0.98
  Number of events 62 17 18 – 27
  Incidence per subject‑year 
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